theMednetRegister

Neurology

ASTRO 2025   

ASTRO 2025 Annual Meeting

Questions discussed in this category

How will you select patients with brain metastases for TTFields?
The METIS study included only NSCLC patients and found a greater impact for patients previously treated with ICI. How does this impact your patient se...
2 Answers available
Would patients receiving targeted therapies be eligible for TTFields for brain metastases?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
3 Answers available
How do you balance short-term efficacy against increased low-grade toxicity and quality-of-life considerations for higher single-fraction regimens in recurrent glioma patients?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
1 Answer available


Papers discussed in this category

Acta neurochirurgica, 2021 Apr 02
Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
The Lancet. Oncology, 2023 Sep
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

Related Topics in Neurology

Copyright © 2025 theMednet
All Rights Reserved.